Overview
- President Donald Trump signed an executive order this month telling the FDA to fast-track psychedelic drug reviews and directing the DEA to create a path for patients to access investigational treatments.
- Texas authorized $50 million to study ibogaine for post‑traumatic stress disorder, opioid addiction, traumatic brain injuries and depression, signaling a major state-level bet on the field.
- At the University of Texas in Austin, researcher Greg Fonzo is enrolling 100 people with treatment‑resistant depression in a study that pairs a single high dose of psilocybin during therapy with a second week of magnetic brain stimulation.
- Psychiatrists and the American Psychiatric Association urge strict screening, close monitoring and long‑term studies, warning about heightened suggestibility, possible psychotic breaks and ethical risks if access expands too fast.
- Investor interest jumped after the order as shares of psychedelic-focused firms rose, yet experts note many treatments require hours of supervised care, specialized staff and costly sessions that could limit access to wealthier patients.